Actively Recruiting
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2025-05-06
300
Participants Needed
7
Research Sites
N/A
Total Duration
Cardiac transthyretin amyloidosis (ATTR) is a condition where misfolded transthyretin protein deposits in the heart, causing thickening of the heart walls and leading to heart dysfunction and failure. Researchers are investigating imaging markers using cardiac magnetic resonance (CMR) techniques like feature tracking and T1- and T2-mapping to better understand disease severity and identify patients who may benefit from treatment that stabilizes transthyretin. The study collects detailed CMR imaging data from patients with amyloidosis, including measures of heart function and tissue characteristics, over an 18-month period after therapy begins. Clinical and laboratory follow-up visits occur every 3 to 6 months. This observational research gathers retrospective and prospective data from patients diagnosed at a single hospital to evaluate how these imaging markers relate to disease progression and treatment response. Participants undergo regular assessments including CMR scans to measure left and right ventricle function, tissue changes, and extracellular volume. The study aims to use these imaging results to predict major adverse cardiac events over a five-year period. Researchers will also monitor clinical status and laboratory values during follow-up visits to better understand the impact of treatment and disease progression.
CONDITIONS
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline assessment
Participants undergo cardiac magnetic resonance imaging (CMR) and clinical assessments to evaluate cardiac amyloidosis and establish baseline measures.
1 visit (in-person)
Duration - Up to 18 months
Participants are monitored with clinical and laboratory follow-up every 3 to 6 months and repeated CMR assessments over 18 months to track disease progression and therapy response.
Follow-up visits every 3 to 6 months
Total: 7 locations
1
USB
Basel, Switzerland, 4031
Not Yet Recruiting
2
Department of Cardiology, University Hospital Bern, Inselspital, Bern
Bern, Switzerland, 3010
Actively Recruiting
3
HUG
Geneva, Switzerland, 1211
Actively Recruiting
4
CHUV
Lausanne, Switzerland, 1011
Actively Recruiting
5
LUKS
Lucerne, Switzerland, 6000
Actively Recruiting
6
KSSG
Sankt Gallen, Switzerland, 9007
Actively Recruiting
7
Stadtspital Triemli
Zurich, Switzerland, 8063
Actively Recruiting
C
Christoph Gräni, MD, PhD
M
Moritz Hundertmark, MD, PhD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Federico Caobelli, Cristina E Popescu, Nasir Gözlügöl...
https://pubmed.ncbi.nlm.nih.gov/41804669Federico Caobelli, Nasir Gözlügöl, Adam Bakula...
https://pubmed.ncbi.nlm.nih.gov/38724281